<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>461-ROPINIROLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with ropinirole and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>461-ROPINIROLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>461-ROPINIROLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ENOXACIN" rxcui="">
<ATC code="J01MA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ropinirole with signs of overdose due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with the enoxacin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>461-ROPINIROLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of ropinirole, with risk of overdose, due to decrease of its hepatic metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with fluvoxamine and after it is stopped. </COMMENT>
</INTERACTION>
</INTERACTIONS>
